Hook / Thesis
Hims & Hers is no longer just a DTC telehealth app selling hair loss or ED treatments. The company is assembling a more diversified healthcare platform: rapid revenue growth, a string of product verticals (mental health, dermatology, sexual health, testosterone/peptides), and international expansion are combining to create a business with material scale economics. For investors willing to navigate regulatory noise, the upside looks meaningful from current levels.
My base case: the company can push from a $7.2 billion market cap today toward a multiple expansion narrative as revenue climbs and gross margins stabilize. Legal and regulatory headlines will keep headline volatility high, so this is a measured long with an explicit stop to control asymmetric downside.
What the business is and why the market should care
Hims & Hers operates a direct-to-consumer telehealth platform connecting consumers to healthcare professionals across multiple specialties - mental health, sexual health, dermatology, and expanding primary care. The platform advantages are threefold: low customer acquisition cost via data-driven digital marketing, recurring-revenue subscription hooks for certain therapies, and an ability to layer higher-ARPU offerings (testosterone, peptides, specialist care) on the same consumer base.
Scale matters here. Management recently reported 38% revenue growth to $753.2 million in a recent quarter and has raised full-year guidance to $3.1 - $3.3 billion. That kind of top-line expansion creates optionality - better unit economics, cross-sell lift, and the ability to absorb regulatory/legal expense without derailing growth initiatives.
Hard numbers that support the thesis
| Metric | Value |
|---|---|
| Current price | $31.05 |
| Market cap | $7.24B |
| Recent quarterly revenue growth | 38% year-over-year to $753.2M |
| Full-year guidance | $3.1B - $3.3B |
| Free cash flow (trailing) | $66.9M |
| EV | $7.71B |
| Price/Sales | ~2.94x |
| Debt / Equity | 2.18 |
Those figures show an enterprise with real growth, improving cash flow and a valuation that implies investors are paying for scale but not for perfection. The price-to-sales near 3x is hefty for a business that still carries legal overhang, but it is reasonable if growth can remain in the 30-40% corridor and margins expand as higher-ARPU products and international revenue mix improves.
Valuation framing
At a $7.2B market cap and an EV of roughly $7.71B, Hims & Hers trades at about 2.9x trailing sales. The company is not profitable on an EPS basis, but it does produce positive free cash flow (~$67M). The negative PE is a non-complete metric given the company's reinvestment phase; valuation should be judged on revenue multiple and the trajectory of gross margins and FCF conversion.
If management hits the raised $3.1 - $3.3B guide and can keep mid-30% growth next year while improving FCF margin toward low single-digits, a 4-5x revenue multiple becomes defendable, which implies a mid-teens to +50% upside from today depending on execution. Conversely, if regulatory penalties or sustained user attrition materialize, the multiple would compress rapidly.
Catalysts (what could push the stock higher)
- GLP-1 and employer coverage dynamics - As employers pare back GLP-1 coverage in 2027, more patients should migrate to telehealth platforms for prescriptions and ongoing management, increasing addressable demand.
- Product expansion monetization - Testosterone replacement and peptides are nearing a $100M annual run-rate; further scaling could materially lift ARPU and gross margins.
- International growth and acquisitions - Management is targeting ~$600M international revenue in 2026; if cross-border rollouts and the Eucalyptus acquisition execute, revenue mix and margins could improve.
- Legal resolution clarity - Quantified settlement or judgment outcomes (and the removal of legal overhang) would likely restore investor confidence and multiple expansion.
Trade plan (actionable)
Direction: Long
Entry price: $31.05
Target price: $48.00
Stop loss: $25.00
Horizon: long term (180 trading days) - allow time for regulatory developments to resolve or clarify, for international and specialty revenue lines to ramp, and for margin / FCF improvements to show up in quarterly results.
Why this plan? Entering at $31.05 gives exposure near current trading levels while the $25 stop limits downside to a level that corresponds with material multiple compression or clear evidence of sustained user loss. The $48 target sits well below the prior 52-week high of $65.30, but is a realistic point where the market would reward continued 30%+ growth and early margin expansion with multiple rerating.
Technical and market structure notes
Technicals are mixed but constructive: the 9/21/50-day EMAs sit around the low $30s and the MACD histogram recently turned positive, suggesting building momentum. RSI is neutral (~50.7), limiting immediate overbought risk. Short interest remains meaningful (~58.7M shares as of mid-August) and short-volume spikes have accompanied recent down days - this creates volatility but also potential squeeze dynamics on positive catalysts.
Risks and counterarguments
- Regulatory / Legal Risk: Multiple investigations and an FTC lawsuit alleging deceptive privacy or billing practices are active. A large FTC judgment, fines, or injunctive remedies could materially impact topline and margins. Management has already taken a legal contingency (~$47.5M) against results, but larger outcomes are possible.
- Reputational and user trust erosion: Privacy allegations can reduce conversion and retention; if customers abandon platform subscriptions, revenue growth could slow and CAC could rise.
- Margin compression from new verticals: New categories like testosterone and peptides can be higher-touch and more expensive to deliver, compressing gross margins relative to legacy subscription therapies.
- Debt load / capital structure: Debt-to-equity is ~2.18, which is notable for a growth-stage healthcare company. A deterioration in cash flow could stress the balance sheet or limit strategic flexibility.
- Counterargument: The bull case assumes the company can scale higher-ARPU categories and international markets quickly. Skeptics point out that customer acquisition in regulated healthcare is harder than consumer categories, unit economics may not improve as expected, and the legal environment could impose recurring compliance costs that blunt margins. If revenue growth slows below guidance or churn increases, the current multiple would look expensive and the stock could re-test its recent lows around $13.74.
What would change my mind
I will turn bearish if any of the following happen: (a) quarterly revenue growth decelerates sharply below 20% with rising churn, (b) a regulatory outcome imposes a multiyear injunction or a settlement materially above current contingencies, or (c) FCF turns negative with sustained cash burn that forces equity dilution. Conversely, I will upgrade conviction if the company reports sequential margin improvement, international revenue hitting the $600M target, and management demonstrates consistent ARPU lift from specialty products.
Conclusion
Hims & Hers is evolving from a narrowly focused telehealth play into a broader healthcare platform with multiple monetization levers. That makes the company a compelling long idea today, but only if the investor accepts pronounced headline risk from regulatory and privacy litigation. My trade plan balances that: participate in upside via a $31.05 entry and $48 target over 180 trading days, while protecting capital with a $25 stop. This is a growth-at-a-risk trade - the runway is real, but so are the hurdles.
Key monitoring points over the next 180 trading days: quarterly revenue and guidance consistency, legal filings and settlements (watch headlines closely), unit economics on new verticals (ARPU and gross margin), and international revenue ramp cadence.